All In Biotech

NDA 019316 · Fresenius Kabi USA

Magnesium Sulfate

Magnesium Sulfate · Intramuscular, Intravenous

Last checked: Nov 20, 2026Latest source record: Mar 5, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Sep 8, 1986

Approved uses

1

Original approval plus efficacy supplements

Registered trials

561

123 Phase 3, 51 recruiting

FAERS reports

13,039

11,779 serious, 2,148 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 2, 2026.

INDICATIONS AND USAGE Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 mEq/L) and the serum calcium level is normal (4.3 to 5.2 mEq/L) or elevated. In total parental nutrition (TPN), magnesium sulfate may be added to the nutriend admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 8, 1986 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • MAGNESIUM SULFATE · MAGNESIUM SULFATE 10GM/20ML (500MG/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS · Prescription · TE AP
  • MAGNESIUM SULFATE · MAGNESIUM SULFATE 5GM/10ML (500MG/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS · Prescription · TE AP
  • MAGNESIUM SULFATE · MAGNESIUM SULFATE 25GM/50ML (500MG/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS · Prescription · TE AP
  • MAGNESIUM SULFATE · MAGNESIUM SULFATE 1GM/2ML (500MG/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Magnesium Sulfate" as an intervention, any sponsor and status, largest first.

All 561 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,204
  • nausea854
  • off label use846
  • pyrexia802
  • maternal exposure during pregnancy772
  • foetal exposure during pregnancy705
  • pain705
  • premature baby686
  • diarrhoea646
  • dyspnoea607
  • hypotension575
  • anaemia565

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004145
2005160
2006199
2007417
2008383
2009481
2010249
2011653
2012586
2013259
2014375
2015361
2016487
2017563
2018640
2019688
2020950
20211,075
20221,096
20231,031
2024863
2025800
2026577

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Magnesium Sulfate (Magnesium Sulfate)

2024 spending

$174K

Beneficiaries

1,025

9,530 claims

Per beneficiary

$170

$0.15 per unit

View as table
YearSpending
2020$151,932
2021$173,602
2022$134,834
2023$169,024
2024$173,951

Part D: Magnesium Sulfate (Magnesium Sulfate In Water)

2024 spending

$34K

Beneficiaries

229

848 claims

Per beneficiary

$148

$0.18 per unit

View as table
YearSpending
2020$13,826
2021$20,802
2022$27,166
2023$20,086
2024$33,858

Part B: Magnesium Sulfate* (Magnesium Sulfate*) · HCPCS J3475

2024 spending

$256K

Beneficiaries

19,942

114,020 claims

Per beneficiary

$13

2024 ASP limit $0.58 per unit

View as table
YearSpending
2020$301,130
2021$370,548
2022$331,697
2023$350,744
2024$256,083

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 854 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.